Trials / Completed
CompletedNCT02604836
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,711 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibandronate | Film-coated oral ibandronate tablet (150 mg) once-monthly |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-04-01
- Completion
- 2006-04-01
- First posted
- 2015-11-13
- Last updated
- 2016-11-02
Locations
142 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02604836. Inclusion in this directory is not an endorsement.